DLK1 (delta-like) is a transmembrane and secreted protein in the epidermal growth factor-like homeotic family. Although expressed widely during embryonic development, only a few tissues retain the expression in adults. Neuroendocrine tumors often highly express this protein; therefore, we hypothesized that brain tumors might also express it. This study found that the expression of DLK1 in gliomas was higher than that in normal brain (Po0.05). After stable transfection of a DLK1 cDNA expression vector into GBM cell lines, their proliferation was increased. Furthermore, they lost contact inhibition, had enhanced anchorage-independent growth in soft agar, and had significantly greater capacity to migrate. Western blot studies showed that expression of cyclin D1, CDK2, and E2F4 were increased, and Rb levels were decreased in these cells. DLK1 was found on the cell surface and secreted in the medium from the transfected GBM cells. DLK1-enriched condition medium stimulated the growth of glioblastoma multiforme cell lines and explants. DLK1 antibody blocked cell growth stimulated by DLK1. In summary, these results suggest that DLK1 may play a role in the formation or progression of gliomas.
Introduction DLK1 (delta-like) is a transmembrane protein. It is a member of the epidermal growth factor-like proteins homologous to Notch/Delta/Serrate, containing a signal peptide followed by six epidermal growth factor-like repeat motifs, a transmembrane domain, and a short intracellular tail (Laborda, 2000) . DLK1 protein, also known as pref-1, SCP-1, Zog, FA1, and pG2 (Lee et al., 1995; Laborda, 2000) , is expressed in a variety of murine and human fetal cells, but it is present only in a limited number of adult tissues (Cooper et al., 1990; Jensen et al., 1993; Laborda et al., 1993; Tornehave et al., 1996; Floridon et al., 2000) . DLK1 participates in several differentiation processes including adipogenesis (Smas and Sul, 1993; Boney et al., 1996; Garces et al., 1999) , hematopoiesis (Moore et al., 1997; Bauer et al., 1998; Kaneta et al., 2000) , and adrenal gland development (Cooper et al., 1990; Gaetano et al., 1992) , as well as wound healing (Samulewicz et al., 2002) ; it is also involved in the control of embryonic growth (Schmidt et al., 2000; Takada et al., 2000; Moon et al., 2002) . A recent report suggests that DLK1 acts as a negative regulator of Notch1 (Baladron et al., 2005) .
Unlike other delta-family members, DLK1 lacks the DSL motif, which is important for the interaction with the Notch family of proteins (Simpson, 1995) . In addition, it is an imprinted gene transcribed from the paternal allele (Schmidt et al., 2000; Takada et al., 2000 Takada et al., , 2002 Wylie et al., 2000) .
DLK1 is highly expressed in neuroblastomas, smallcell lung carcinomas, and neuroendocrine tumors (Laborda et al., 1993; van Limpt et al., 2000) , suggesting that it may play a role in their tumorigenesis. We find that the gene has increased expression in 1/3 of the glioblastoma multiforme (GBM) compared to normal brain tissues. Forced expression of DLK1 in subclones of GBM cell lines enhanced their transformed phenotype.
Results

DLK1 is overexpressed in gliomas
DLK1 is expressed in many embryonic tissues, but expression becomes limited to only a few tissues in adults. Neuroendocrine tumors express abundant DLK1. Therefore, we investigated if brain tumors expressed prominent levels of this gene. mRNAs were isolated from 51 quick-frozen glioma samples and five normal brain samples. Each tumor sample was con-firmed histologically. Reverse transcription, real-time PCR was used to measure the relative cDNA copy number of DLK1 (Table 1 ). The expression of DLK1 in gliomas was higher than that in normal brain (Po0.05). Ten of 31 tumor samples (32%) had markedly elevated DLK1 levels (twofold greater expression than the highest DLK1 value in the normal brain sample). Western blot analysis showed higher expression of DLK1 protein in GBM (Figure 1 ).
DLK1 promotes proliferation of GBM cells
To explore further the role of DLK1 in human brain tumors, full-length human DLK1 cDNA was cloned into the eucaryotic expression vector pcDNA3.1 (pcDNA-DLK1), and stably placed in GBM cell lines T98G, U87, U118 (T98G/D, U87/D, U118/D). The neoexpressing vector pcDNA3.1 was placed in the same GBM cell lines as controls (T98G/neo, U87/neo, U118/ neo). As expected, DLK1 was highly expressed in the pcDNA-DLK1-transfected cells, but not in the pcDNA3.1 vector-transfected cells as shown by Western analysis (Figure 2) .
The T98G/D, U87/D, U118/D stable subclones grew faster than the control cells (wild-type cells and pcDNA3.1-transfected cells) as measured by MTT assay (Figure 3a) . Also, the percentage of T98G/D (clones b and c) cells in S phase of the cell cycle (4475; 4072%, respectively) was threefold greater than the percentage of T98G/neo cells in S phase (1472%) as shown by pulse-exposure to BrdU (Po0.0001) (Figure 3b) . Furthermore, expression of proteins associated with an enhanced cell growth (CDK2, cyclin D1, E2F4) was increased, and a protein associated with decreased cell growth (Rb) was decreased in T98G/DLK1-b and T98G/DLK1-c clones compared to the wild-type T98G/w and T98G/neo cells (Figure 3c ). DLK1 promotes growth in soft gel culture, cell migration, loss of contact inhibition The T98G/DLK1 and U87/DLK1 clones formed significantly (>10-fold) more colonies in soft agar than did the control cells (Po0.0001) (Figure 4a ). Furthermore, the clones formed by the T98G/D and U87/D clones were larger than those formed by the control cells (data not shown).
To determine whether enhanced expression of DLK1 influenced cell migration, the ability of T98G/D and T98G/neo to transverse a vitronectin-coated Boyden chamber was measured. The DLK1 stably transfected clones (T98G/D-b and -c) had significantly (Po0.05) increased the number of migratory cells compared with the neo vector-transfected T98G/neo cells (Figure 4b) .
The T98G/D cells piled on top of each other after they reached confluence, appearing to lose contact inhibition; (Figure 5a ). Also after growing to confluence (3.3 Â 10 5 /well), the T98G/DLK1 cells continued to replicate rapidly, whereas the T98G and T98G/neo cells no longer increased in number ( Figure 5b ).
DLK1 is a transmembrane, as well as, secreted protein DLK1 was previously shown to be a transmembrane and secreted protein in several cell types (Smas et al., 1994; Garces et al., 1999) . Fluorescence-activated cell sorting (FACS) showed that abundant amounts of DLK1 protein were present on the cell membrane of T98G/D cells (Figure 6a ). Also, DLK1 was detected in the culture medium of T98G/D cells (Figure 6b ). The signal sequence and C-terminus of DLK1 were presumably cleaved during secretion of the protein, resulting in its slightly reduced size compared to the cellular DLK1 (Figure 6b ).
Condition medium containing DLK1 stimulates growth of GBM cells GBM cell lines (T98G, U87, U118, U343, U373) and GBM explants (JM94, MM156) were cultured in condition medium enriched for DLK1 as described in the Materials and methods (T98G/D cells produced the experimental conditioned medium and T98G/neo cells produced the control conditioned medium). The proliferation of GBM target cells was stimulated in the DLK-enriched media compared to the same cells grown in control conditioned media (Figure 7a ). Addition of DLK1 antibody to either the DLK1-enriched condition media or the T98G/D cells significantly (Po0.001) blocked the growth-stimulatory properties of the DLK1 (Figure 7b and c).
DLK1 downregulates expression of Hes-1 A previous study reported that DLK1 may function as a negative regulator of Notch1 signaling; these investigators found that increased DLK1 expression was associated with decreased Hes-1 expression in either confluent Balb/c 14 cells or 3T3-L1 preadipocytes (Baladron et al., 2005) . We examined the effect of DLK1 on expression of Hes-1 in glioma cells by realtime RT-PCR. Levels of Hes-1 RNA in DLK1-transfected cells (T98G/D, clones b, c, d, e) were reduced more than 50% ( Figure 8a ). Also, after treatment with DLK1-enriched condition medium, the levels of Hes-1 in T98G cells decreased in a timedependent manner ( Figure 8b ).
Discussion
DLK1 is expressed by a variety of fetal and a limited number of adult tissues (Cooper et al., 1990; Tornehave et al., 1993 Tornehave et al., , 1996 Moore et al., 1997) . The pattern of expression suggests DLK1 functions in the development and differentiation of hematopoietic and neuroendocrine tissues (Laborda, 2000) . Furthermore, DLK1 is highly expressed in the adrenal medullary neuroendocrine tumors (Helman et al., 1987) 
, and U118 GBM cell lines stably transfected with DLK1 expression vector. Human DLK1 cDNA in pcDNA3.1 eucaryotic expression vector was transfected into GBM cell lines and stable transfectants were selected for G418 resistance (500 mg/ ml). Single colonies were isolated, and DLK1 expression was confirmed by Western blot. Wild-type GBM cell lines: T98G/w, U87/w, and U118/w; GBM cell lines stably expressing neo gene alone: T98G/neo, U87/neo, and U118/neo; GBM subclones stably expressing DLK1 DLK1 associated with oncogenic activities in gliomas D Yin et al that DLK1 might behave as a proto-oncogene enhancing the malignant behavior of undifferentiated tumors (Laborda et al., 1993; Tornehave et al., 1993; Halder et al., 1998) . In the present study, DLK1 was highly expressed in about 32% of GBM, 8% astrocytomas, and 14% oligodendrogliomas.
DLK1 belongs to the EGF-like superfamily of proteins. These proteins are associated with the extracellular membrane and are released into the extracellular medium ( Figure 6 ). DLK1 is thought to participate in protein/protein interactions though its EGF-like repeats (Carpenter and Zendegui, 1986; Engel, 1989 ; Muska- . Cells (80% confluence) were pulsed with BrdU (1 h), harvested, exposed to BrdU antibody as well as propidium iodide, and analysed by flow cytometry. Three experiments were carried out for each cell type (representative experiment shown). (c) Western blot analysis for levels of proteins involved in the cell cycles: CDK2, cyclin D1, E2F-4, and Rb (GADPH used as loading control).
DLK1 associated with oncogenic activities in gliomas D Yin et al vitch and Hoffmann, 1990) . These repeats are closely related to the structure of those that are found in the developmental control proteins of Drosophila, such as Delta, Serrate, and Notch (Laborda, 2000) . Many of the homologues appear to play a role in tumor formation in humans (Capobianco et al., 1997; Mark et al., 1997; Edwards, 1999) . As a member of the EGF-like superfamily of proteins, we found that DLK1 was expressed on the extracellular membrane and released into the extracellular medium of the GBM cells stably expressing DLK1 ( Figure 6 ). Also, we found that the DLK1-enriched condition medium stimulated the growth of GBM cell lines and explants (Figure 7a ), and this enhanced growth was blocked by DLK1 antibody (Figure 7b ), suggesting that the enhanced growth was not mediated by additional factors in condition medium. Cellular differentiation depends on specific environmental signals that alter intracellular gene expression affecting cellular metabolism and growth. Tumor cells evolve towards an undifferentiated, highly proliferative, invasive cellular phenotype. Constitutive expression of DLK1 in preadipocytes drastically inhibits their differentiation (Smas and Sul, 1993) . During human mesenchymal stem cell (hMSC) differentiation, overexpression of DLK1 maintains the size of the bipotential progenitor cell pool by inhibiting the formation of mature osteoblasts and adipocytes (Abdallah et al., 2004) .
Forced expression of DLK1 in the GBM cell lines (T98G, U87, U118), which had constitutively low expression of DLK1, markedly stimulated several parameters: (1) growth in liquid culture; (2) anchorage-independent cell growth in soft agar; (3) enhanced migration; (4) loss of contact inhibition with the cells piling on top of each other rather than growing as a smooth lawn. In addition, DLK1-expressing GBM cells were often associated with altered expression of cell cycle-related proteins in the S phase of the cell cycle (Figures 3 and 5) .
The above findings in the human GBM cells are in contrast to studies with murine Balb/c 3T3 cells. In response to glucocorticoids, Balb/c 3T3 cells had diminished levels of DLK1 and grew faster (Baladron et al., 2002) . In addition, Gaetano et al. (1992) found that the neuroblastoma cell line SMS-KCNR, cultured with dibutyryl cyclic AMP (dbcAMP), had a markedly increased expression of DLK1 associated with a transition to a more mature chromaffin phenotype with no change in the cell cycle. Therefore, the association of DLK1 and the state of proliferation and differentiation of the cell may be dependent on the cell type and its environmental signals.
Notch signaling plays a key role in maintaining the balance between cell proliferation and differentiation. The oncogenic potential of Notch-1 has been shown in T-cell leukemia in which the truncated form of Notch-1 is expressed (Ellisen et al., 1991) . On the other hand, Notch1 can cause growth arrest in medulloblastomas, mammalian skin tumors, and small-cell lung cancers (Sriuranpong et al., 2001; Nicolas et al., 2003; Fan et al., 2004) . DLK1 is a negative regulator of Notch1 activation and decreases expression of Hes-1 (a downstream target of Notch-1) in 3T3-L1 fibroblasts (Baladron et al., 2005) . In this study, we found that the expression of Hes-1 was decreased in DLK1-overexpressing GBM cells and GBM cells grown in DLK1-enriched cultured medium. The expression of Hes-1 was reported to be required for the growth inhibitory effect of all-trans retinoic acid in breast cancer cells ( In conclusion, we show for the first time that DLK1 is increased in expression in GBM as measured by real-time RT-PCR and Western blot. DLK1 promotes GBM proliferation in liquid culture, migration, and anchorageindependent growth in soft agar. These cells lose contact inhibition and grow on top of each other. Western blot analysis shows that expression of proliferation-enhancing proteins (cyclin D1, CDK2, and E2F4) are increased, and levels of the tumor suppressor gene Rb are decreased in DLK1-expressing GBM cells. DLK1 is a transmembrane and secreted protein, and the DLK1 may stimulate growth of GBM cells in a paracrine and autocrine fashion. This may be mediated though altering the activity of Notch. Taken together, these results suggest that DLK1 may play a role in progression of GBM.
Materials and methods
Cell culture GBM cell lines and explants were maintained in Dulbecco's modified Eagle's medium (Gibco, BRL) with 10% fetal calf serum (Gemini Bio-Products, Calabasas, CA, USA), 10 U/ml penicillin-G, and 10 mg/ml streptomycin (Gemini Bio-Products, Calabasas, CA, USA). All cells were incubated at 371C in 5% CO 2 . The real-time PCR was performed as described previously using a standard curve to determine the quantity of DLK1 mRNA (Yin et al., 2002) . We also quantified transcripts of b-actin as the endogenous control. The amount of DLK1 mRNA was divided by the level of b-actin mRNA to obtain a normalized target value. The relative expression of DLK1 mRNA was also normalized to a calibrator (mean value); we selected the mean DLK1 mRNA value of five normal samples as the calibrator. Therefore, the relative expression of each sample was shown as N-fold difference to the calibrator. Primers and probe of the DLK1 gene for realtime PCR were designed employing software PRIMER3 (www.genome.wi.mit. edu/cgibin/primer/primer3www.cgi) according to the nucleotide sequences of Genebank accession number NM_003836. Forward primer, AAGGACTGCCAG AAAAAGGAC, was on exon 4 and reverse primer, GCAG AAATTGCCTGAGAAGC, was on exon 5. The probe was GCCTCCCATGCCTCCTGCCT. Primers and probe for b-actin were: 5 0 TCCCTGGAGAAGAGCTACGA (forward), 5 0 AGGAAGGAAGGCTGGAAGAG (reverse), 5 0 CAATGA GCGGTTCCGCTGCC (probe). Real-time PCR was performed on the iCycler iQt system (Bio-Rad, Hercules, CA, USA). The PCR product of Hes-1 was measured via a fluorescent signal generated by the binding of the fluorophore SybrGreen during the PCR. The amplification was followed by 45 cycles with 941C for 20 s, 601C for 10 s, 651C for 25 s, and a fluorescence read step at 871C for 25 s. b-Actin cDNA was used to normalize the expression data of Hes-1; Hes-1 primers: AAGGCGGACATTCTGGAAAT (forward), GTCACCTCG TTCATGCACTC (reverse). All experiments were carried out in triplicate. The variance of threshold cycle values between the triplicates was o5%. The values of copy number of DLK1 cDNA were used to determine relative expression of DLK1. The relative copy number of DLK1 cDNA in brain tissue samples was calculated from the DLK1 standard curve of realtime PCR and normalized to the relative copy number of b-actin in each sample.
RNA isolation and reverse transcription real-time PCR
Cell transfection and soft agar assays
The expression vector pcDNA-DLK1 was constructed by placing full-length human DLK1 cDNA into the pcDNA3.1 eucaryotic expression vector containing the neomycin gene (Invitrogen). The constructs were transfected into human GBM cells by using lipofectamine and transfectants were selected by G418 resistance (500 mg/ml). The selected clones were confirmed by Western blot analysis. For clonogenic assays, cells were plated into 24-well flat-bottomed plates using a two-layer soft agar system with a total of 1 Â 10 3 cells/well in a volume of 400 ml/well, as described previously (Munker et al., 1986) . After 14 days of incubation, the colonies were counted. All experiments were carried out three times using triplicate plates per experimental point.
Cell migration assays
Cell migration assays were performed according to the protocol from Chemicon (Temecula, CA, USA). 5 Â 10 4 cells were added to the top of each modified Boyden chamber (10 mm thickness and 8 mm pores) containing polycarbonate membranes (6.5 mm diameter) coated on the underside of the membrane with 10 mg/ml vitronectin, and the lower chamber contained 500 ml of migration buffer (medium with 0.5% BSA). Cells were allowed to migrate to the underside of the top chamber for 6 h. The migratory cells attached to the bottom surface of the membrane were stained with 0.1% crystal violet in 0.1 M borate, pH 9.0 and 2% ethanol for 20 min at room temperature. The stained cells were extracted by using extraction buffer (Chemicon, Temecula, CA, USA). The number of migratory cells per membrane was determined by absorbance at 550 nm. (Experiments were repeated three times, with similar results.) (b) Secretion of DLK1. T98G/neo and T98G/D-c cells were grown to 60% confluence, washed with PBS buffer, and cultured with Dulbecco's modified Eagle's medium without fetal calf serum for 48 h. Medium was collected, concentrated (10-fold), and subjected to Western blotting as described in Materials and methods. DLK1 was detected in the conditioned medium of T98G/D-c; molecular size was slightly less than DLK1 from cell lysates of T98G/D-c, probably as a result of cleavage of the C-terminus of the protein during release from the cell membrane.
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Cell proliferation analysis Cells that were stably transfected with either pcDNA3.1-DLK1 or pcDNA3.1 empty vector were plated into 96-well plates at 5 Â 10 2 cells/well. After culturing for various durations, cell numbers were measured by MTT assay according to the protocol provided by Roche Molecular Biochemicals (Basel, Switzerland).
Western blot analysis
Cells were harvested for total cell lysates with RIPA buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5) containing a mixture of protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) as well as 1 mM NaF and 1 mM NaVO 4 . Cell lysates were centrifuged at 13 000 r.p.m. for 10 min at 41C. Supernatants were collected, and protein concentrations were measured. Lysates (30 mg) were denatured in sample buffer (10% glycerol, 5% b-mercaptoethanol, 2.3% SDS, 62.5 mM Tris-HCl, pH 6.8) by boiling and then subjected to 4-5% SDS-PAGE followed by electrotransfer to polyvinylidene difluoride membrane. Immune complexes were visualized with Supersignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA), and normalized by internal control (GAPDH). Antibodies were from Santa Cruz Biotechnology Inc. (California, USA). 
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Cell cycle analysis Cells were plated in 100-mm dishes and BrdU was added to the medium for 1 h when they reached 80% confluence. After trypsinizing and washing twice with phosphate-buffered saline, cells were fixed in 70% ice-cold ethanol overnight. The samples were denatured and exposed to fluorescence antibody to BrdU and propidium iodide, and analysed by flow cytometry (FACScan, Becton Dickinson).
Flow cytometric analysis FACS analysis was performed using DLK1 antibody (1:500) (Santa Cruz). After washing the primary antibody with PBS, the cells were incubated with fluorescein isothiocyanateconjugated anti-goat IgG (5 mg/ml) at 41C for 30 min. The cells were washed again with PBS. FACS sorting was performed using a FACScan (Becton Dickinson), and analysis was performed using CellQuest 2.0 (Becton Dickinson, Mountain View, CA, USA).
Collection of DLK1 in the culture medium When T98G/neo and T98G/D cells grew to 60% confluence, they were washed with PBS buffer and cultured with Dulbecco's modified Eagle's medium (DMEM, Gibco, BRL) without fetal calf serum. After culturing for 48 h, the medium was collected and concentrated by centrifugal filtration through a YM-10 (Millipore, Bedford, MA. USA).
Cell culture with DLK1 condition medium When T98G/D and T98G/neo cells grew to over 80% confluence, old DMEM medium was changed to G418-free medium. After 24 h, their medium was used as condition medium to be added to candidate cells in 96-well plate (500 cells/well), and the medium from T98G/neo was used as control medium. After 5 days, the growth of cells in the conditioned medium was measured by MTT.
Cell culture in condition medium with DLK1 antibody DLK1 antibody (Santa Cruz Biotechnology Inc., CA, USA) was diluted 50-fold, and concentrated by centrifugal filtration through a YM-10 (Millipore, Bedford, MA, USA) to remove the sodium azide. T98G cells (5000 cells/well, 24-well plate) were cultured in condition medium from T98G/D, either without or with DLK1 antibody (2 mg/ml), and the medium from T98G/neo was used as a control medium. After 6 days, the number of T98G cells was counted. T98G/D cells were treated with 2 mg/ml DLK1 antibody, the medium with goat IgG was used as control medium, and the number of T98G/D cells was measured by MTT.
Statistical analysis
Student's t-test was used to compare data from the two groups.
Abbreviations GBM, glioblastoma multiforme; T98G/w, U87/w, and U118/ w, wild-type GBM cell lines (T98G, U87, and U118); T98G/ neo, U87/neo, and U118/neo, T98G, U87, U118 cells transfected with neo-containing vector; T98G/D, U87/D, and U118/D, T98G, U87, U118 cells stably transfected with the DLK1 expression vector; FACS, fluorescence-activated cell sorting. 
